• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

功能精准医学：将药物作用于患者癌细胞并观察效果。

Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens.

作者信息

Letai Anthony

机构信息

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

出版信息

Cancer Discov. 2022 Feb;12(2):290-292. doi: 10.1158/2159-8290.CD-21-1498.

DOI:10.1158/2159-8290.CD-21-1498
PMID:35140175
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8852353/
Abstract

For too long, assays exposing patient tumor cells to drugs to identify active therapies have been dismissed as ineffective. In this issue of , two groups independently demonstrate clinical utility of such functional precision medicine assays in hematologic malignancies...

摘要

长期以来，将患者肿瘤细胞暴露于药物以确定有效疗法的检测方法一直被认为是无效的而被摒弃。在本期杂志中，两个研究小组独立证明了这种功能精准医学检测方法在血液系统恶性肿瘤中的临床应用价值……

相似文献

1
Functional Precision Medicine: Putting Drugs on Patient Cancer Cells and Seeing What Happens.功能精准医学：将药物作用于患者癌细胞并观察效果。
Cancer Discov. 2022 Feb;12(2):290-292. doi: 10.1158/2159-8290.CD-21-1498.
2
[Precision medicine in hematological malignancies].
Rinsho Ketsueki. 2019;60(9):1386-1395. doi: 10.11406/rinketsu.60.1386.
3
Precision Cancer Medicine: Large Studies Indicate Steady Progress.
Cancer Discov. 2021 Nov;11(11):2677-2678. doi: 10.1158/2159-8290.CD-21-1069.
4
Think Globally, Act Locally: Globalizing Precision Oncology.放眼全球，立足本地：精准肿瘤学全球化。
Cancer Discov. 2022 Apr 1;12(4):886-888. doi: 10.1158/2159-8290.CD-22-0024.
5
Next-Generation Profiling of Medulloblastoma: Old Drugs Are an Elegant Weapon in a Civilized Age.《成神经管细胞瘤的新一代分析：旧药物在文明时代是一种优雅的武器》
Cancer Res. 2021 Jan 15;81(2):264-265. doi: 10.1158/0008-5472.CAN-20-3708.
6
Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription.实体瘤和血液恶性肿瘤的药物基因组学：改善个体化药物处方
Therapie. 2022 Mar-Apr;77(2):171-183. doi: 10.1016/j.therap.2021.11.003. Epub 2021 Nov 25.
7
Decoding the Noncoding Cancer Genome.解码非编码癌症基因组。
Cancer Discov. 2020 May;10(5):646-647. doi: 10.1158/2159-8290.CD-20-0285.
8
Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game.精准肿瘤学的联合疗法：终极打地鼠游戏。
Clin Cancer Res. 2021 May 15;27(10):2672-2674. doi: 10.1158/1078-0432.CCR-21-0254. Epub 2021 Mar 11.
9
Precision medicine-based drug treatment individualization in oncology.肿瘤学中基于精准医学的药物治疗个体化
Br J Clin Pharmacol. 2021 Feb;87(2):223-226. doi: 10.1111/bcp.14512. Epub 2020 Dec 13.
10
Precision Medicine in Pediatric Oncology.儿科肿瘤学中的精准医学
Surg Oncol Clin N Am. 2020 Jan;29(1):63-72. doi: 10.1016/j.soc.2019.08.005. Epub 2019 Oct 29.

引用本文的文献

1
Patient-derived organotypic tumor spheroids, tumoroids, and organoids: advancing immunotherapy using state-of-the-art 3D tumor model systems.患者来源的器官型肿瘤球体、类肿瘤和类器官：利用先进的3D肿瘤模型系统推进免疫治疗。
Lab Chip. 2025 Jun 24;25(13):3038-3059. doi: 10.1039/d5lc00062a.
2
Osteosarcoma cells depend on MCL-1 for survival, and osteosarcoma metastases respond to MCL-1 antagonism plus regorafenib in vivo.成骨肉瘤细胞依赖 MCL-1 存活，并且成骨肉瘤转移对 MCL-1 拮抗加瑞戈非尼的体内治疗有反应。
BMC Cancer. 2024 Nov 4;24(1):1350. doi: 10.1186/s12885-024-13088-7.
3
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma.在进行治疗干预之前，对治疗反应进行功能预测与提高高级别胶质瘤患者的生存率相关。
Sci Rep. 2024 Aug 29;14(1):19474. doi: 10.1038/s41598-024-68801-0.
4
Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer.斑马鱼替身试验预测结直肠癌患者对化疗的临床反应。
Nat Commun. 2024 Jun 5;15(1):4771. doi: 10.1038/s41467-024-49051-0.
5
Translating p53-based therapies for cancer into the clinic.将基于 p53 的癌症疗法转化为临床应用。
Nat Rev Cancer. 2024 Mar;24(3):192-215. doi: 10.1038/s41568-023-00658-3. Epub 2024 Jan 29.
6
What is Next in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia.儿童B细胞前体急性淋巴细胞白血病的下一步是什么。
Lymphatics. 2023 Jun;1(1):34-44. doi: 10.3390/lymphatics1010005. Epub 2023 May 12.
7
BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics.作为BH3模拟物活性药效学生物标志物的BH3分析
Haematologica. 2024 Apr 1;109(4):1253-1258. doi: 10.3324/haematol.2023.283060.
8
Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.多组学数据在分子肿瘤委员会中的整合揭示了炎性肌纤维母细胞瘤患者中与 EGFR 相关的 ALK 抑制剂耐药性。
Oncologist. 2023 Aug 3;28(8):730-736. doi: 10.1093/oncolo/oyad129.
9
Novel Zebrafish Patient-Derived Tumor Xenograft Methodology for Evaluating Efficacy of Immune-Stimulating BCG Therapy in Urinary Bladder Cancer.新型斑马鱼患者来源肿瘤异种移植方法用于评估免疫刺激卡介苗疗法在膀胱癌中的疗效。
Cells. 2023 Feb 3;12(3):508. doi: 10.3390/cells12030508.
10
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine.深度形态学学习增强基于药物表型分析的体外精准医疗。
Blood Cancer Discov. 2022 Nov 2;3(6):502-515. doi: 10.1158/2643-3230.BCD-21-0219.

本文引用的文献

1
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.实施急性髓系白血病功能性精准医学肿瘤委员会
Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17.
2
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.功能精准医学为晚期侵袭性血液系统恶性肿瘤提供临床获益，并鉴定出具有优异缓解率的患者。
Cancer Discov. 2022 Feb;12(2):372-387. doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11.
3
Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.对治疗表现出异常反应的癌症的分子特征
Cancer Cell. 2021 Jan 11;39(1):38-53.e7. doi: 10.1016/j.ccell.2020.10.015. Epub 2020 Nov 19.
4
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.卓越反应者倡议：美国国家癌症研究所试点研究的可行性。
J Natl Cancer Inst. 2021 Jan 4;113(1):27-37. doi: 10.1093/jnci/djaa061.
5
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.分子靶向药物联合治疗在髓系和淋巴系血液系统恶性肿瘤中显示出选择性疗效。
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.
6
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.通过快速抑制剂筛选确定原发性人类白血病中的激酶途径依赖性。
Cancer Res. 2013 Jan 1;73(1):285-96. doi: 10.1158/0008-5472.CAN-12-1906. Epub 2012 Oct 18.
7
American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays.美国临床肿瘤学会临床实践指南更新：化疗敏感性和耐药性检测的应用。
J Clin Oncol. 2011 Aug 20;29(24):3328-30. doi: 10.1200/JCO.2011.36.0354. Epub 2011 Jul 25.
8
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.美国临床肿瘤学会技术评估：化疗敏感性和耐药性检测
J Clin Oncol. 2004 Sep 1;22(17):3631-8. doi: 10.1200/JCO.2004.05.065. Epub 2004 Aug 2.
9
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.一种BCR-ABL酪氨酸激酶特异性抑制剂在慢性髓性白血病中的疗效与安全性
N Engl J Med. 2001 Apr 5;344(14):1031-7. doi: 10.1056/NEJM200104053441401.
10
Initial sequencing and analysis of the human genome.人类基因组的初步测序与分析。
Nature. 2001 Feb 15;409(6822):860-921. doi: 10.1038/35057062.